Q-omics provides the consensus-scored MAS1L profile across patient tissues and cancer cell-line models. MAS1L expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAS1L is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, MAS1L RNA expression shows 12,908 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where MAS1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAS1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAS1L survival associations across molecular data types. MAS1L RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAS1L RNA expression–survival associations across cancer types. High MAS1L expression shows unfavorable associations in THCA, but favorable associations in KIRC, LUAD, ESCA, BRCA and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAS1L RNA expression.
This table summarizes MAS1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MAS1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAS1L shows lower tumor expression in COAD, BLCA, LUSC, LUAD, BRCA and UCEC. The COAD box plot shows higher MAS1L RNA expression in normal versus tumor tissue (log2 FC = −0.641, t-test p < 0.001).
This table shows molecular features associated with MAS1L in patient tissues and cancer cell lines. In patient samples, MAS1L shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MAS1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and KIDNEY.
